These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 21807295)

  • 1. Polypill and global cardiovascular health strategies.
    Sanz G; Fuster V
    Semin Thorac Cardiovasc Surg; 2011; 23(1):24-9. PubMed ID: 21807295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maximizing therapeutic envelope for prevention of cardiovascular disease: role of polypill.
    Sanz G; Fuster V
    Mt Sinai J Med; 2012; 79(6):683-8. PubMed ID: 23239207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polypill: quo vadis?
    Muscente F; De Caterina R
    J Cardiovasc Med (Hagerstown); 2016 Nov; 17(11):783-92. PubMed ID: 27341194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The polypill: An effective approach to increasing adherence and reducing cardiovascular event risk.
    Bramlage P; Sims H; Minguet J; Ferrero C
    Eur J Prev Cardiol; 2017 Feb; 24(3):297-310. PubMed ID: 27798363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution of the polypill concept and ongoing clinical trials.
    Castellano JM; Sanz G; Fuster V
    Can J Cardiol; 2014 May; 30(5):520-6. PubMed ID: 24786442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 'Multiple action fixed combination. Present or future?'.
    García-Donaire JA; Ruilope LM
    Fundam Clin Pharmacol; 2010 Feb; 24(1):37-42. PubMed ID: 20002751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A polypill strategy to improve adherence: results from the FOCUS project.
    Castellano JM; Sanz G; Peñalvo JL; Bansilal S; Fernández-Ortiz A; Alvarez L; Guzmán L; Linares JC; García F; D'Aniello F; Arnáiz JA; Varea S; Martínez F; Lorenzatti A; Imaz I; Sánchez-Gómez LM; Roncaglioni MC; Baviera M; Smith SC; Taubert K; Pocock S; Brotons C; Farkouh ME; Fuster V
    J Am Coll Cardiol; 2014 Nov 18-25; 64(20):2071-82. PubMed ID: 25193393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is prevention a fantasy, or the future of medicine? A panoramic view of recent data, status, and direction in cardiovascular prevention.
    Kones R
    Ther Adv Cardiovasc Dis; 2011 Feb; 5(1):61-81. PubMed ID: 21183531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel therapeutic concepts: the epidemic of cardiovascular disease in the developing world: global implications.
    Gersh BJ; Sliwa K; Mayosi BM; Yusuf S
    Eur Heart J; 2010 Mar; 31(6):642-8. PubMed ID: 20176800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The challenge of polypharmacy in cardiovascular medicine.
    Volpe M; Chin D; Paneni F
    Fundam Clin Pharmacol; 2010 Feb; 24(1):9-17. PubMed ID: 19817871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polypill: an affordable strategy for cardiovascular disease prevention in low-medium-income countries.
    López-Jaramillo P; González-Gómez S; Zarate-Bernal D; Serrano A; Atuesta L; Clausen C; Castro-Valencia C; Camacho-Lopez P; Otero J
    Ther Adv Cardiovasc Dis; 2018 Jun; 12(6):169-174. PubMed ID: 29546816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cardiovascular polypill in high-risk patients.
    Lafeber M; Spiering W; Singh K; Guggilla RK; Patil V; Webster R;
    Eur J Prev Cardiol; 2012 Dec; 19(6):1234-42. PubMed ID: 22019908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Asymptomatic peripheral arterial disease: is pharmacological prevention of cardiovascular risk cost-effective?
    Sigvant B; Henriksson M; Lundin F; Wahlberg E
    Eur J Cardiovasc Prev Rehabil; 2011 Apr; 18(2):254-61. PubMed ID: 21450673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cholesterolemia control in Spain, 2000. A tool for cardiovascular disease prevention. Ministry of Health and Consumption, Spanish Society of Cardiology and Spanish Society of Arteriosclerosis].
    Rev Esp Salud Publica; 2000; 74(3):215-53. PubMed ID: 10918811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The polypill: a potential global solution to cardiovascular disease.
    Nguyen C; Cheng-Lai A
    Cardiol Rev; 2013; 21(1):49-54. PubMed ID: 23018668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The polypill in the primary prevention of cardiovascular disease.
    Wald DS; Wald NJ
    Fundam Clin Pharmacol; 2010 Feb; 24(1):29-35. PubMed ID: 20002198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Fixed-dose compounds and the secondary prevention of ischemic heart disease].
    Fuster V; Sanz G
    Rev Esp Cardiol; 2011 Jul; 64 Suppl 2():3-9. PubMed ID: 21807282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can we prevent cardiovascular diseases in low- and middle-income countries?
    Lenfant C
    Bull World Health Organ; 2001; 79(10):980-2; discussion 983-7. PubMed ID: 11693981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A polypill strategy to improve global secondary cardiovascular prevention: from concept to reality.
    Castellano JM; Sanz G; Fernandez Ortiz A; Garrido E; Bansilal S; Fuster V
    J Am Coll Cardiol; 2014 Aug; 64(6):613-21. PubMed ID: 25104532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Public health. Experts debate polypill: a single pill for global health.
    Reardon S
    Science; 2011 Sep; 333(6051):1813. PubMed ID: 21960602
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.